Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 76-year-old man presents to the outpatient clinic with a 3-day history of profound nausea, generalized weakness, and decreased appetite. He also reports that his vision has acquired a "yellowish tint." His medical history includes ischemic cardiomyopathy with a left ventricular ejection fraction of 30%, chronic kidney disease stage 3a, and paroxysmal atrial fibrillation. His home medications include lisinopril, metoprolol succinate, furosemide, apixaban, and digoxin 0.25 mg daily. One week ago, amiodarone was added to his regimen for increasing episodes of symptomatic atrial fibrillation.

Vital signs show a blood pressure of 105/65 mm Hg and a heart rate of 52/min with an irregularly irregular rhythm.

Laboratory evaluation reveals:

TestResultReference Range
Serum potassium3.1 mEq/L3.5-5.0 mEq/L
Serum creatinine1.5 mg/dL0.6-1.2 mg/dL
Serum digoxin3.2 ng/mL0.5-2.0 ng/mL

Which of the following are the most appropriate immediate steps in the monitoring and treatment evaluation of this patient? (Select exactly 2 options)

  1. Withhold the digoxin therapy and obtain a 12-lead electrocardiogramCevap
  2. Initiate oral potassium chloride supplementationCevap
  3. C
    Administer intravenous digoxin-specific antibody fragments
  4. D
    Increase the furosemide dosage to enhance renal excretion
  5. E
    Arrange for urgent hemodialysis to remove the circulating drug

Cevap

The correct steps are to withhold the digoxin therapy, obtain a 12-lead electrocardiogram, and initiate oral potassium chloride supplementation.
The correct course of action involves withholding the digoxin therapy, obtaining a 12-lead electrocardiogram, and initiating oral potassium chloride supplementation. The addition of amiodarone inhibited P-glycoprotein, reducing digoxin clearance and precipitating toxicity. Because digoxin and potassium compete for the same binding site on the myocardial Na+/K+-ATPase pump, hypokalemia directly exacerbates digoxin toxicity. Therefore, holding the drug, monitoring for arrhythmias via an ECG, and normalizing the potassium level are the required definitive next steps.

Adım Adım Çözüm

1
Analyze the clinical presentation and medication changes.
The patient exhibits classic symptoms of digoxin toxicity (nausea, weakness, xanthopsia) precipitated by the recent addition of amiodarone, a known P-glycoprotein inhibitor that increases serum digoxin levels.
Identifying the root cause of the patient's deterioration is essential for correct management. Digoxin doses typically need to be reduced by 50% when amiodarone is initiated.
2
Interpret the laboratory findings in the context of the toxicity.
The digoxin level is supratherapeutic (3.2 ng/mL). The serum potassium is low (3.1 mEq/L).
Digoxin competes with potassium for binding sites on the Na+/K+-ATPase pump. Hypokalemia leaves more binding sites available for digoxin, severely worsening its toxic effects at the tissue level, even if the serum level is only moderately elevated.
3
Select the appropriate therapeutic interventions.
The necessary steps are to stop the digoxin, assess for silent or evolving cardiac arrhythmias with an electrocardiogram, and cautiously replete the potassium deficit.
These conservative measures address the immediate risks without prematurely escalating to invasive or high-risk antidotal therapies.

Anahtar Kavram

Management of pharmacologic interactions precipitating digoxin toxicity, emphasizing the critical role of potassium correction.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru